Pathways Study: Puberty Suppression

Debate between Lizzi Collinge and James Murray

Monday 22nd June 2026 Commons Chamber

[James Murray]

I thank the right hon. Gentleman for his comments, and although he and I come to a different conclusion on this, I do not doubt for a second the sincerity of his motivation in wanting to protect children and young people. I actually agree with him, as I said in my earlier comments, that most young children who are questioning their gender will resolve it on their own—let them be to resolve it. But there is a small subset of children who will need extra support, and within that there is a question about whether for a very small subset of them there might be a benefit to having treatment, and that is what this trial seeks to conclude.

I would add that the right hon. Gentleman refers to what happened in the Tavistock clinic and the stories that led to Dr Hilary Cass being commissioned. I think the right hon. Gentleman and I agree on how unacceptable that situation was, and I put on record my thanks to Sir Sajid Javid for commissioning the work by Dr Cass, because it has been such an important piece of work not only to expose what was happening before, but to provide a way forward.

[Lizzi Collinge (Morecambe and Lunesdale) (Lab)]

Puberty suppressors have been used for many years for precocious puberty, but the evidence base for their use in gender dysphoria lacked rigour, so I welcome the news that the trial will go ahead, as recommended by the Cass review. Will the Secretary of State confirm that the medications are only one part of the research, and can he outline some of the other measures being looked at? Given the small numbers expected to take part in this trial, will research also be undertaken into the impact on young people who are showing gender distress but are unable to access a trial or, of course, be prescribed puberty blockers, in order to get a full clinical picture? Will he furthermore ensure that all young children showing gender distress will have some care and support?

[James Murray]

My hon. Friend rightly points out that the clinical trial—the Pathways study, which is the subject of this statement—is just one part of the wider work being done to make sure that the support is there for children and young people who are questioning their gender and who might, or might not, need support in order to feel well about themselves. The Pathways horizon is an observational study of all children and young people attending NHS children and young people’s specialist gender services. Pathways connect is a brain-imaging study. Pathways voices will interview young people. Horizon intensive is about making sure that there is a comparison group of 300 participants who are expressing gender incongruence but not receiving puberty-suppressing hormones, as my hon. Friend suggested.